A RANDOMIZED, PLACEBO-COTROLLED PILOT STUDY OF THE EFFECTS OF ONCE

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 矿物质磷含量非常高， 保护性胆固醇组分高密度脂蛋白（HDL） 胆固醇通常存在于慢性肾病患者中， 导致心脏病（包括致死性心脏病）的CKD 疾病，以及CKD进展为肾衰竭。目前日 降低磷的治疗需要摄入多种药丸 每日三次，这是一种对患者产生负面影响的负担 遵守和生活质量。烟酸化合物，包括慢 每天释放一次产品，降低血清磷水平， 提高肾衰竭患者的HDL水平。我们计划评估 每日一次口服烟酸产品对血清磷的影响 在不太晚期的CKD患者中， 发展成肾衰竭这些信息将帮助我们评估烟酸的 作为一种简单、廉价和耐受性良好的治疗方法， 肾脏疾病患者的磷水平升高较低。 最终，烟酸可能被认为是一种降低风险的药物 心脏病和进展为肾衰竭。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Very increased levels of the mineral phosphorus, and low level of the protective cholesterol fraction high density lipoprotein (HDL) cholesterol are found commonly in patients with chronic kidney disease (CKD) contributing to heart disease, including fatal heart disease, and the progression of CKD to kidney failure. Current daily phosphorus lowering treatments require the intake of multiple pills three times daily, a burden which negatively affects patient compliance and quality of life. Niacin compounds, including slow release once daily products, lower serum phosphorus levels, and raise HDL levels in patients with kidney failure. We plan to assess the effect of a once daily oral niacin product on serum phosphorus levels in patients with less advanced CKD, before such patients might develop kidney failure. This information will help us evaluate niacin's potential as a simple, inexpensive, and well-tolerated treatment to lower elevated phosphorus in patients with kidney disease. Eventually, niacin may be considered as an agent to reduce the risk for heart disease and progression to kidney failure in these patients.